In the global hyperbaric oxygen therapy landscape, North America stands as the undisputed leader within the Hyperbaric Oxygen Therapy Market . The region accounts for over 54.77% of the global market revenue, generating approximately USD 700 million. This dominant position is built on a foundation of a highly advanced healthcare system, a high prevalence of chronic wounds, and strong adoption of advanced therapeutic technologies.

The United States is the primary engine of this market, holding an 84% share within the region, valued at USD 587.52 million. The country has a high burden of chronic conditions such as diabetes and cardiovascular disease, which often lead to complications like non-healing wounds. The CDC estimates that over 6.5 million patients in the U.S. suffer from chronic wounds, creating a substantial and sustained demand for hyperbaric oxygen therapy. The U.S. healthcare system's emphasis on value-based care and reducing hospital readmissions drives the adoption of HBOT for wound care, as it has been shown to improve healing rates and reduce amputations.

The presence of leading hyperbaric chamber manufacturers such as OxyHeal (US) , Hyperbaric Medical Solutions (US) , and Sechrist Industries (US) fosters a robust ecosystem of innovation and clinical research. These companies are continuously developing more efficient, user-friendly, and technologically advanced hyperbaric chambers. The U.S. Food and Drug Administration's regulatory framework ensures product safety and efficacy, building confidence among healthcare providers and patients. Favorable reimbursement policies from the Centers for Medicare & Medicaid Services (CMS) for HBOT in approved indications also support patient access.

Canada, holding a 16% share valued at USD 111.91 million, also contributes to the region's leadership, supported by expanding healthcare infrastructure and increasing adoption of hyperbaric therapies. The Canadian healthcare system's focus on chronic disease management and wound care drives demand for HBOT solutions. As technological leadership, patient awareness, and supportive reimbursement structures continue to characterize the region, North America is expected to maintain its dominant position in the global hyperbaric oxygen therapy market, serving as a hub for innovation and clinical excellence.